View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Pierre FerraguÊ
  • Pierre FerraguÊ

Tariffs & Semicap equipment: the baseline & what’s next.

Evaluating the consequences of tariffs is challenging. As we strengthen our understanding of the tech supply chain, we follow-up on our initial analysis to evaluate the impact on semicap equipment with more precision. This follows our recent deep dives on the impact on Nvidia, Broadcom, and AMD/Intel. Read also our broader notes on tariffs: our baseline thesis for an overall perspective, and our assessment of the macro risk.

Guy Sips ... (+10)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Lewi

Morning Notes : FLOW NA, FUR NA, GLPG NA, KIN BB, KPN NA, XFAB FP, AZE...

: FLOW NA, FUR NA, GLPG NA, KIN BB, KPN NA, XFAB FP, AZE BB, IMCD NA, ONWD BB, AUTL US, EXO NA, ZEAL DC, PHVS US

Thomas Vranken
  • Thomas Vranken

Onward Medical FIRST LOOK: US ADR program established

Onward has launched an ADR program in the US, allowing American investors to trade Onward shares more easily in USD. Each ADR represents one ordinary Onward share and trades on the OTCQX market under the symbol ONWRY. This move aims to attract US institutional investors, enhance share liquidity, and broaden Onward's shareholder base. While it does not affect the company's cash position or shares outstanding, it could boost visibility, paving another step in the way for a potential future US IPO....

 PRESS RELEASE

ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX ...

ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch BNY will be ADR depositary bank Ticker symbol for US investors is ONWRY EINDHOVEN, the Netherlands, April 24, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and OTCQX: ONWRY), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilit...

 PRESS RELEASE

ASML discloses 2025 AGM results

ASML discloses 2025 AGM results ASML discloses 2025 AGM results Veldhoven, the Netherlands, April 23, 2025 –  ASML Holding N.V. (ASML) today announces the results of its Annual General Meeting (AGM) held on April 23, 2025. At the AGM, ASML’s statutory financial statements for the 2024 financial year were adopted. In addition, the following items were approved:  Proposal to adopt a final dividend payment of €1.84 per ordinary share, which, together with the two interim dividends paid through the 2024 financial year and the interim dividend paid in February 2025, each €1.52 per ordinary s...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AkzoNobel: 3% beat on 1Q25 Adj. EBITDA, FY25 guidance maintained at +€1.55bn. BE Semiconductor Industries: 1Q25 results - extending the downcycle. Corbion: Apogee. Just Eat Takeaway.com: 1Q25 Trading Update - no impact on the bid. Kinepolis: 1Q25 preview. KPN: 1Q25 preview. Randstad: Strong 9% high quality beat on 1Q25, 2Q25 outlook looks a touch below. Vår Energi: Fine start of the year, more to come. Vopak: Reasonable start, cashflow developing nicely.

Kristof Samoy ... (+5)
  • Kristof Samoy
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste

Morning Notes : AKZA NA, BESI NA, CRBN NA, CMBT BB, FLOW NA, RAND NA, ...

: AKZA NA, BESI NA, CRBN NA, CMBT BB, FLOW NA, RAND NA, VPK NA, TKWY NA

Wim Hoste
  • Wim Hoste

Akzo Nobel FIRST LOOK: 1Q adj EBITDA -2%, FY guidance of € 1.55bn EBIT...

Akzo's 1Q adjusted EBITDA decreased by 2% and came in c. 3% below our forecast and c. 3% above consensus. FY25 adj EBITDA guidance of above €1555m is maintained and calls for at least 5% growth, whilst most of the predicted growth comes from self help measures. Taking into account the volatile track record and low structural growth, we maintain our Hold rating and € 65 TP.

Guy Sips ... (+5)
  • Guy Sips
  • Jacob Mekhael
  • Kristof Samoy
  • Michiel Declercq
  • Wim Lewi
Pierre FerraguÊ
  • Pierre FerraguÊ

TSMC & ASML signals, Auto semi recovery, and more. The Tech Weekly Wra...

As always, during earnings season, we wrap-up what happened in the previous week. For our main takes summarized on a single slide, and a few words on each of the 14 names we followed last week, follow the link below.

 PRESS RELEASE

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value14-Apr-25108,722€596.15€64,815,00115-Apr-25107,327€603.93€64,818,21016-Apr-25---17-Apr-2521,660€566.97€12,280,62018-Apr-25-*- - *Markets closed ASML’s current share buyback program was announced on 10 November 2022, and details are available on o...

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
 PRESS RELEASE

DEME announces start of new share buyback program

DEME announces start of new share buyback program Based on the shareholder authorization granted by the Extraordinary General Meeting of June 29, 2022, the Board of Directors of DEME Group NV has decided to launch a new share buyback program.   Attachment

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch